ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer

 
• By Dexter Jie Yan

In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.

ovarian cancer
Platinum-resistant ovarian cancer has a mostly poor prognosis • Source: Shutterstock

More from ASCO

More from Conferences